Try
ADMA BIOLOGICS, INC.
ADMAUnited States
86 filed reports · 616 financial concepts · 0 earnings calls · 0 media appearances
Filed reports
86 reports · Sep 2011 to Jun 2026Each report counts once it has at least one extracted financial fact. Also extracted from these reports: 75 guidance figures.
| Report type | Reports | Facts | Periods |
|---|---|---|---|
| Quarterly · 10-QSEC EDGAR | 46 | 7,636 | Sep 2011 to Jun 2026 |
| Current · 8-KSEC EDGAR | 26 | 75 | Dec 2020 to Jun 2026 |
| Annual · 10-KSEC EDGAR | 14 | 5,650 | Dec 2012 to Dec 2025 |
Documents
| Period | Type | Period end | Published | Facts | Source |
|---|---|---|---|---|---|
| FY2026 Q2 | 8-K | Jun 30, 2026 | Aug 5, 2026 | 2 | Open |
| FY2026 Q2 | 10-Q | Jun 30, 2026 | Aug 5, 2026 | 413 | Open |
| FY2026 Q1 | 8-K | Mar 31, 2026 | May 6, 2026 | 2 | Open |
| FY2026 Q1 | 10-Q | Mar 31, 2026 | May 6, 2026 | 273 | Open |
| FY2025 Q4 | 8-K | Dec 31, 2025 | Feb 25, 2026 | 3 | Open |
| FY2025 | 10-K | Dec 31, 2025 | Feb 25, 2026 | 837 | Open |
| FY2025 Q4 | 8-K | Dec 31, 2025 | Jan 12, 2026 | 5 | Open |
| FY2025 Q3 | 8-K | Sep 30, 2025 | Nov 5, 2025 | 3 | Open |
| FY2025 Q3 | 10-Q | Sep 30, 2025 | Nov 5, 2025 | 253 | Open |
| FY2025 Q2 | 8-K | Jun 30, 2025 | Aug 6, 2025 | 2 | Open |
| FY2025 Q2 | 10-Q | Jun 30, 2025 | Aug 6, 2025 | 156 | Open |
| FY2025 Q1 | 10-Q | Mar 31, 2025 | May 7, 2025 | 155 | Open |
Financial data
616 concepts · 13,361 factsEach concept is one reported line item or metric. The count is how many values of it are held, across the periods shown.
Financial578 concepts · 10,826 facts · Jun 2006 to Jul 2026
- Stockholders equity (US GAAP)87 · Jun 2006 to Jun 2026
- Net income loss84 · Jun 2007 to Jun 2026
- Cash and cash equivalents at carrying value82 · Jun 2010 to Jun 2026
- Increase decrease in accrued liabilities79 · Sep 2010 to Jun 2026
- Net cash provided by used in operating activities79 · Sep 2010 to Jun 2026
- Operating expenses (US GAAP)79 · Sep 2010 to Jun 2026
- Other cost and expense operating79 · Sep 2010 to Jun 2026
- Additional paid in capital77 · Jun 2011 to Jun 2026
- Assets77 · Jun 2011 to Jun 2026
- Common stock par or stated value per share77 · Jun 2011 to Jun 2026
- Common stock shares authorized77 · Jun 2011 to Jun 2026
- Common stock shares issued77 · Jun 2011 to Jun 2026
- Common stock shares outstanding77 · Jun 2011 to Jun 2026
- Common stock value77 · Jun 2011 to Jun 2026
- Depreciation and amortization77 · Mar 2011 to Jun 2026
- Increase decrease in accounts payable77 · Mar 2011 to Jun 2026
- Increase decrease in accounts receivable77 · Mar 2011 to Jun 2026
- Increase decrease in inventories77 · Mar 2011 to Jun 2026
- Liabilities and stockholders equity77 · Jun 2011 to Jun 2026
- Liabilities current77 · Jun 2011 to Jun 2026
- Net cash provided by used in financing activities77 · Mar 2011 to Jun 2026
- Operating income loss77 · Mar 2011 to Jun 2026
- Research and development expense77 · Mar 2011 to Jun 2026
- Share based compensation77 · Mar 2011 to Jun 2026
Segment32 concepts · 2,315 facts · Jun 2011 to Jun 2026
- Revenue310 · Dec 2011 to Jun 2026
- Depreciation and amortization249 · Jun 2011 to Jun 2026
- Operating income loss237 · Jun 2011 to Sep 2024
- Nonoperating income expense161 · Jun 2011 to Jun 2026
- Net income loss147 · Jun 2016 to Dec 2023
- Cost of revenue (US GAAP)146 · Jun 2017 to Jun 2026
- Income loss from continuing operations before income taxes extraordinary items noncontrolling interest110 · Jun 2011 to Jun 2026
- Total Assets96 · Mar 2018 to Jun 2026
- Cost of goods sold92 · Mar 2012 to Mar 2018
- Gross profit (US GAAP)91 · Mar 2012 to Dec 2018
- Property and equipment, net76 · Jun 2011 to Dec 2016
- Payments to acquire property plant and equipment64 · Mar 2018 to Mar 2023
- Total assets59 · Mar 2015 to Dec 2019
- Other nonoperating income expense58 · Mar 2018 to Mar 2021
- Operating Segments57 · Jun 2020 to Dec 2023
- Segment expenditure addition to long lived assets54 · Dec 2021 to Jun 2026
- Gains losses on extinguishment of debt47 · Mar 2019 to Dec 2023
- ADMA BioManufacturing40 · Jun 2019 to Mar 2021
- Capital expenditures36 · Sep 2016 to Dec 2019
- Gain loss on sale of other assets29 · Mar 2019 to Sep 2020
- General and administrative expense (US GAAP)28 · Dec 2022 to Jun 2026
- Research and development expense28 · Dec 2022 to Jun 2026
- Selling and marketing expense (US GAAP)28 · Dec 2022 to Jun 2026
- Other cost and expense operating24 · Dec 2022 to Dec 2025
Geography1 concepts · 79 facts · Jun 2020 to Jun 2026
- Revenue79 · Jun 2020 to Jun 2026
Guidance3 concepts · 75 facts · Jan 2021 to Aug 2026
- Revenue Guidance61 · Jan 2021 to Aug 2026
- Net Income Guidance12 · Jan 2024 to Jan 2025
- Revenue Growth Guidance2 · Jan 2023
Product2 concepts · 66 facts · Jun 2020 to Dec 2025
- Research and development expense38 · Sep 2021 to Dec 2025
- Revenue28 · Jun 2020 to Dec 2022
Segments
2,460 factsFigures broken down by business line, region, product or another axis the company reports on.
Statement business segments14 members · 2,315 facts
- Corporate570 · Jun 2011 to Sep 2024
- Plasma Collection Center454 · Jun 2011 to Mar 2021
- ADMA Bio Manufacturing334 · Jun 2020 to Jun 2026
- Plasma Collection Centers315 · Jun 2020 to Jun 2026
- Adma Biomanufacturing257 · Jun 2016 to Mar 2021
- Research And Development211 · Jun 2011 to Mar 2017
- Consolidated78 · Jun 2019 to Mar 2021
- Corporate26 · Mar 2018 to Sep 2024
- Admabio manufacturing segment25 · Jun 2020 to Jun 2026
- Plasma collection centers segment25 · Jun 2020 to Jun 2026
- Adma biomanufacturing8 · Mar 2018 to Mar 2021
- Plasma collection center8 · Mar 2018 to Mar 2021
- Adma biomanufacturing2 · Dec 2019 to Dec 2020
- Plasma collection center2 · Dec 2019 to Dec 2020
Statement geographical2 members · 79 facts
- US40 · Jun 2020 to Jun 2026
- Non Us39 · Jun 2020 to Jun 2026
Product or service4 members · 66 facts
- ASCENIV23 · Sep 2021 to Dec 2025
- BIVIGAM15 · Sep 2021 to Dec 2025
- License And Service14 · Jun 2020 to Dec 2022
- Product14 · Jun 2020 to Dec 2022
Text from filings
Management commentary and risk factors, extracted from SEC filings only.
No commentary or risk-factor text for this company.
Earnings calls
Transcripts with management claims and analyst questions, one per fiscal period.
No earnings-call transcripts for this company.
Executive media
Podcasts, interviews and conference appearances by the company's executives, with their claims.
No media appearances for this company.
Reports are counted as filed reports with at least one served fact. Counts are read from the database (last read Oct 16, 2026) and refreshed every few hours.